Stockscreener 앱 받기
15.88
0.87%
-0.14
시간 외 거래:
15.55
-0.33
-2.08%
전일 마감가:
$16.02
열려 있는:
$16.49
하루 거래량:
131.04K
Relative Volume:
9.46
시가총액:
$319.37M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$14.97
$16.49
1주일 범위
$14.97
$17.50
52주 변동 폭
$14.97
$17.50
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
LBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
15.88 | 322.00M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Lb Pharmaceuticals Inc 주식(LBRX)의 최신 뉴스
Novo-Backed Drug Developer MapLight Therapeutics Files for IPO - Bloomberg.com
Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO - MSN
Layoff Tracker: Arsenal, X4 Lay Off Half of Staff to Cut Costs - BioSpace
Hedge Fund and Insider Trading News: Ray Dalio, Bill Ackman, Warren Buffett, Steve Cohen, Mario Gabelli, Balyasny Asset Management, LB Pharmaceuticals Inc (LBRX), Avista Corp (AVA), and More - Insider Monkey
Schizophrenia drug developer LB Pharma jumps in trading debut - MSN
Wednesday 9/17 Insider Buying Report: LBRX, RAPP - Nasdaq
Major Investors Make Bold Moves in LB Pharmaceuticals Stock! - TipRanks
Vida Ventures raises $5.0m in LB Pharmaceuticals (LBRX) By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Launches $285 Million Initial Public Offering - Global Legal Chronicle
Vida Ventures raises $5.0m in LB Pharmaceuticals (LBRX) - Investing.com
Finance Watch: LB Pharmaceuticals Launches Second-Largest Biopharma IPO Of 2025 In The US - insights.citeline.com
Strong demand for LB Pharma in rare NASDAQ IPO: Public Equity Report - biocentury.com
LB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debut - Yahoo Finance
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering - Mintz
Form 424B4 LB PHARMACEUTICALS INC - StreetInsider
Neuro drug maker LB Pharmaceuticals raises $285 million in U.S. IPO - MSN
LB Pharma valued at $382 million as shares jump in New York debut - Reuters
LB Pharmaceuticals Jumps 27% After Raising $285 Million in IPO - Bloomberg.com
LB Pharmaceuticals shares rise nearly 27% giving biotech valuation of about $382 million - TradingView
Cooley-Led LB Pharmaceuticals Raises Upsized $285M IPO - Law360
Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - GlobeNewswire
LB Pharmaceuticals Opens At $19, IPO Priced At $15 By Investing.com - Investing.com Canada
LB Pharma Pushes the Biotech IPO Window Open, Bagging $285M for Key Schizophrenia Drug Trial - MedCity News
Biopharma breaks its lengthy IPO drought - Axios
LB Pharmaceuticals Prices $285 Million IPO - MarketScreener
LB Pharmaceuticals prices upsized IPO at $15 per share By Investing.com - Investing.com Nigeria
Neuro drug maker LB Pharmaceuticals raises $285 million in U.S. IPO (LBRX:Pending) - Seeking Alpha
LB Pharmaceuticals prices upsized IPO at $15 per share - Investing.com
LB Pharma prices $285M Nasdaq debut to help develop schizophrenia drug - Endpoints News
LB Pharmaceuticals raises $285 million in US IPO - 1470 & 100.3 WMBD
LBRXLB Pharmaceuticals Latest Stock News & Market Updates - Stock Titan
LB Pharma raises $285M in IPO - Axios
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering - The Manila Times
LB Pharmaceuticals raises $285M in first major biotech IPO since February - BioPharma Dive
$285 Million IPO: Biotech LB Pharmaceuticals Prices Upsized Offering at $15 with Strong Institutional Support - Stock Titan
LB Pharmaceuticals Announces Pricing Of Its Upsized Initial Public Offering - TradingView
IPO Opinion | LB Pharmaceuticals (NASDAQ:LBRX) - Seeking Alpha
LB Pharmaceuticals Files for IPO - MarketScreener
LB Pharma targets $250 million raise in bold IPO move - The Pharma Letter
After a long biotech IPO lull, LB Pharma chances its arm - pharmaphorum
LB Pharmaceuticals targets $322M valuation in IPO for schizophrenia drug - Axios
LB Pharmaceuticals Inc. (LBRX): Schizophrenia Biotech Sets Terms, Readies for Same-Week Debut - Smartkarma
LB Pharma seeks $228M in proposed IPO with hopes to be industry’s first since February - Endpoints News
Lb Pharmaceuticals Inc (LBRX) 재무 분석
Lb Pharmaceuticals Inc (LBRX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.43%
0.09%
자본화:
|
볼륨(24시간):